8-K current report · filed Nov 16, 2026

MapLight Therapeutics, Inc. (MPLT) 8-K Current Report: November 16, 2026

Item 2.02Item 7.01Item EX-99.1Item EX-99.2MPLT overview

Short answer

MapLight Therapeutics, Inc. (MPLT) filed an 8-K current report with the SEC on November 16, 2026 reporting Item 2.02 (Results of Operations and Financial Condition), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1), Item EX-99.2 (Exhibit EX-99.2). Q3 2026 financial results for quarter ended September 30, 2026.

MapLight Therapeutics, Inc. 8-K event analysis

AI summary of each reported item and its exhibits

Item 2.02 · Results of Operations and Financial Condition

  • Q3 2026 financial results for quarter ended September 30, 2026
  • Investor-relevant figures and management commentary contained in Exhibit 99.1 press release

Item 7.01 · Regulation FD Disclosure

  • Updated corporate presentation signals refreshed investor messaging as of November 16, 2026
  • Presentation available on MapLight Therapeutics’ website and furnished as Exhibit 99.2
  • Investors should review Exhibit 99.2 for updated pipeline, clinical, financing or corporate developments

Item EX-99.1 · Exhibit EX-99.1

  • Q3 net loss $51.6M, versus $29.4M, reflecting sharply higher clinical development spending
  • Cash, equivalents and investments $463.4M, expected to fund operations through 2028 and key clinical readouts
  • ZEPHYR-2 Phase 3 startup underway for schizophrenia, with topline results expected in 2028
  • VISTA Phase 2 enrollment ongoing in approximately 300 ADP participants, with topline results expected second half 2027
  • ML-007C-MA prioritized while significant investment in early-stage programs is paused, concentrating capital on lead assets

Item EX-99.2 · Exhibit EX-99.2

  • Corporate presentation dated November 16, 2026 highlights ML-007C-MA as the lead schizophrenia and Alzheimer’s disease psychosis asset
  • ZEPHYR-1 met its primary endpoint, with PANSS effect size 0.37 and cognitive composite effect size 0.51
  • ML-007C-MA showed 7.1% discontinuations due to treatment-emergent adverse events and 2.0% due to gastrointestinal events
  • Planned ZEPHYR-2 pivotal study could support an NDA, subject to FDA End-of-Phase 2 feedback
  • Cash of approximately $463M supports a runway through 2028, funding near-term clinical milestones

Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean

Other MapLight Therapeutics, Inc. 8-K filings

Get the next MPLT 8-K as it lands

Follow MPLT for push alerts, or ask the research agent what this filing means.